CRISPR’s Journey From Molecular Scissors to Precision Genome Editors

When CRISPR-Cas9 first burst onto the scene, it was celebrated as a pair of molecular scissors: a programmable nuclease that could be guided to almost any DNA sequence and cut it with unprecedented ease. That simplicity transformed biology almost overnight, but it also exposed the technology’s limitations. Cutting a genome is a blunt act, and the cell’s repair of those cuts is often unpredictable. A new review published in Molecular Genetics and Genomics by Mohadese Rahbari, Reyhane Lohrasbi and Amir Amiri-Yekta traces how the field has moved decisively beyond that early scissor paradigm, charting a decade of refinement in which precision, safety and predictability have become the central measures of progress in therapeutic genome editing.

The review begins where the technology itself began: in prokaryotes. CRISPR-Cas systems evolved as adaptive immune defenses in bacteria and archaea, storing fragments of viral DNA in genomic memory banks and using them to recognize and destroy invading genetic material. When researchers realized that this bacterial immune machinery could be reprogrammed with a single guide RNA to target nearly any sequence of interest, the implications were enormous. Early CRISPR-Cas9 experiments demonstrated remarkable efficiency and ease of use compared with earlier genome-editing platforms such as zinc-finger nucleases and transcription activator-like effector nucleases, which required laborious protein engineering for each new target.

Yet the honeymoon was short-lived. As clinical ambitions grew, so did concern over off-target effects, the unwanted edits that occur when the Cas9 nuclease acts at sites that only partially match the guide RNA. Variable editing outcomes, unpredictable insertions and deletions at the target site, and the risk of large genomic rearrangements all limited the technology’s broader application to human therapy. The review emphasizes that these technical shortcomings, alongside delivery inefficiencies that make it difficult to get editing machinery into the right cells in the right tissues, remain among the field’s most persistent challenges even as the toolkit has grown far more sophisticated.

The evolution from scissors to editors is best embodied by the rise of base editing and prime editing. Rather than relying on double-strand breaks and the cell’s error-prone repair pathways, these newer approaches chemically convert individual DNA letters or write short new sequences with minimal collateral damage. The review highlights work demonstrating that prime editing can correct oncogenic KRAS variants without the constraints imposed by traditional CRISPR-Cas9 workflows, and that CRISPR-based strategies have achieved efficient correction of both KRAS and TP53 mutations, two of the most frequently mutated genes in human cancer. Such results illustrate the conceptual shift: the goal is no longer simply to disrupt a gene but to rewrite it precisely, restoring normal function rather than merely silencing a faulty instruction.

Cancer therapy has emerged as one of the most active arenas for these refined tools. The review surveys how CRISPR-Cas9 library screening has accelerated anti-cancer drug discovery by systematically identifying genes that tumors depend on, and how ex vivo editing of immune cells is reshaping immunotherapy. Chimeric antigen receptor T cells engineered with CRISPR have shown that targeting the CAR construct to a defined genomic locus, such as the TRAC locus, can enhance tumor rejection compared with randomly integrated vectors. Editing of natural killer cells and T cells from human donors is being pursued for cancer immunotherapy, and strategies to improve CAR-T cell persistence through CRISPR-mediated knockout of exhaustion-related pathways are advancing through preclinical and clinical pipelines.

Beyond cancer, the review catalogs applications across viral disease, autoimmune conditions and inherited disorders. CRISPR-based approaches are being developed to engineer resistance to viruses, with HIV-1/AIDS therapy representing a prominent example in which editing aims to remove or disable viral genomes integrated into host DNA. Diagnostic platforms derived from CRISPR nucleases, including SHERLOCK and DETECTR, exploit the sequence-specific recognition of Cas enzymes to detect viral nucleic acids with high sensitivity, offering rapid tools for emerging infectious diseases. In autoimmune disease research, genome editing is being used to dissect and potentially correct the immune dysregulation that underlies conditions such as lupus and rheumatoid arthritis, pointing toward a future in which the immune system itself can be retuned at the genetic level.

None of these therapeutic visions can be realized without solving the delivery problem, and the review devotes substantial attention to the technologies that ferry editing machinery into cells. Viral vectors, particularly adeno-associated virus and lentiviral vectors, offer efficient gene transfer but raise questions about payload capacity, insertional risks and immune responses. Non-viral alternatives include physical methods such as electroporation and microinjection, lipid nanoparticles and solid lipid nanoparticles, cell-penetrating peptides, DNA nanocarriers and extracellular vesicles. Nanotechnology-based delivery of CRISPR components for cancer treatment is a particularly active frontier, with gold nanoparticles and other platforms being evaluated for biocompatibility and cytotoxicity under evolving regulatory frameworks. The choice of delivery vehicle, the review makes clear, often determines whether an elegant editing strategy can ever reach the clinic.

Even when editing succeeds, the human body may object. Immunogenicity of the bacterial Cas9 protein is a recognized concern, since many people carry pre-existing antibodies and T cells reactive to common Cas variants from environmental exposure to the microbes that harbor them. The review also confronts the ethical dimensions that shadow every advance in the field. The prospect of human germline and heritable genome editing has prompted a global policy debate about where the lines should be drawn, and ethicists have argued that the moral considerations raised by such a powerful tool demand attention to accessibility, consent and the long-term consequences of permanent genomic change. Who will be able to afford these therapies, and how societies will govern their use, remain unresolved questions that the technical community cannot answer alone.

What emerges from the review is a portrait of a technology on a clear trajectory. Engineered Cas variants, such as PAM-flexible chimeric Cas9 proteins that relax the sequence constraints on where editing can occur, are expanding the addressable space of the genome. High-fidelity nucleases reduce off-target activity, base and prime editors increase the precision of the intended change, and improved delivery systems broaden the range of treatable tissues. Together these refinements position CRISPR as an increasingly precise platform for both fundamental research and therapeutic use, supporting targeted therapies for genetic disorders in ways that the original scissor paradigm could never achieve. The authors, based at the University of Science and Culture and the Royan Institute in Tehran, frame this progression not as a completed project but as an ongoing evolution toward greater specificity, safety and predictability.

The clinical momentum is already visible. Approved CRISPR-based therapies for hemoglobin disorders have demonstrated that genome editing can deliver durable benefit in patients, and dozens of trials are testing edited cell therapies, in vivo editing and CRISPR-enabled diagnostics across a widening spectrum of disease. The remaining obstacles, off-target editing, delivery inefficiency, immune reactions and equitable access, are formidable but no longer conceptual; they are engineering and policy problems with active research programs attached to each. As Rahbari, Lohrasbi and Amiri-Yekta conclude, the story of therapeutic genome editing is one of steady refinement, in which the crude power of the original molecular scissors is being progressively replaced by the controlled, predictable hand of a true genome editor. The precision revolution they describe is redefining what medicine can attempt at the level of DNA itself, and the pace of that redefinition shows no sign of slowing.

Subject of Research: The evolution of CRISPR-based genome editing from early nuclease cutting tools toward precise therapeutic platforms for genetic disease

Article Title: From scissors to editors: how the evolution of precision is redefining therapeutic genome editing

Article References: Rahbari, M., Lohrasbi, R., & Amiri-Yekta, A. (2026). From scissors to editors: how the evolution of precision is redefining therapeutic genome editing. Molecular Genetics and Genomics, 301(1), Article 193. https://doi.org/10.1007/s00438-026-02467-3

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02467-3

Keywords: CRISPR-Cas9, genome editing, gene therapy, base editing, prime editing, off-target effects, cancer immunotherapy, CAR-T cells, viral vectors, nanoparticle delivery, precision medicine, genetic disorders